"MorNuCo Laboratories of West Lafayette Indiana and their ONCOblot Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma with the exciting results that the ONCOblot test detected a molecular marker that is indicative of the presence of mesothelioma  years in advance of clinical symptoms appearing. MorNuCo Laboratories is elated to share these results with the public as early detection is widely considered the corner stone of an effective strategy to reduce cancerrelated deaths.  Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos. In this study the serum presence of a mesotheliomaspecific form of the ENOX protein a recently identified marker of malignancy was found within the serum of asbestosexposed individuals an average of . years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test. Serum samples that were collected from asbestosexposed individuals prior to the development of mesothelioma as part of a cancer surveillance program were tested for ENOX protein presence to determine how long in advance of clinical symptoms that the mesotheliomaspecific ENOX protein transcript variants could be detected. The results of this study showed that two mesotheliomaspecific ENOX protein transcript variants were detected in the serum of asbestosexposed individuals  years prior to clinical diagnosis of malignant mesothelioma an exciting sign of progress in the cancer detection field.  The completion of this trial is an exciting new chapter for our work says Nick Miner Vice President of Business Development. Although asbestosinduced mesothelioma is a very specific example of early detection we are currently pursuing largerscale clinical trials to investigate the utility of the ENOX protein marker to predict the onset of cancers of other tissues of origin as well. Miner continued. Although the fight against cancer often appears to be an overwhelmingly intransigent problem significant progress is being made regarding the development of additional tools for cancer detection such as the ONCOblot Test.   About ONCOblot  The ONCOblot Test was developed and created by Dr. D. James Morr and Dr. Dorothy M. Morr of MorNuCo Inc. located in the Purdue Research Park West Lafayette IN. The Morrs are committed to the premise that understanding cancer is the key to its conquest. The ONCOblot test is based on more than  years of basic research. The ONCOblot test is a Laboratory Developed Test LDT that was developed at MorNuCo Inc. The ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT. A k application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.  If youd like more information about the ONCOblot Test please visit http or email infooncoblotlabs.com mailtoinfooncoblotlabs.com  If youd like to read the clinical study please visit httpclinicalproteomicsjournal.biomedcentral.comarticles.s"